Περίληψη:
Purpose: To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam against nonbiologic systemics in psoriasis patients for whom oral systemic or topical therapy is considered appropriate in seven European countries. Methods: Matching-adjusted indirect comparisons of four-week PASI-75 responses of Cal/BD foam were performed versus 12-week responses of methotrexate, acitretin, fumaric acid esters (FAE) and 16-week responses of apremilast. Analyses took a payer perspective and included drug, physician visit and monitoring costs. Results: In all countries, Cal/BD foam generated the lowest cost per responder (CPR). Against methotrexate, apremilast and acitretin, Cal/BD foam generated response for less than €190 in Italy, €195 in Portugal, €216 in Greece, £218 in the United Kingdom, €250 in Belgium, €319 in Spain, and €359 in the Netherlands. Relative to treatment with FAE, Cal/BD foam resulted in response for less than €298, €430, €382 and £262 in Belgium, the Netherlands, Spain and the United Kingdom, respectively. For Cal/BD foam, apremilast and FAE, total costs were driven by drug costs; for methotrexate and acitretin, by monitoring. Conclusions: Driven by its lower costs and high response rates, Cal/BD foam is likely to be a cost-effective option over the short-term in the investigated psoriasis population. © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Συγγραφείς:
Balak, D.M.W.
Carrascosa, J.-M.
Gregoriou, S.
Calzavara-Pinton, P.
Bewley, A.
Antunes, J.
Nyeland, M.E.
Viola, M.G.
Sawyer, L.M.
Becla, L.
Λέξεις-κλειδιά:
apremilast; betamethasone dipropionate plus calcipotriol; dimethyl fumarate; etretin; methotrexate; betamethasone; betamethasone-17,21-dipropionate; calcipotriol; calcitriol; dermatological agent, adult; Article; Belgium; clinical effectiveness; comparative effectiveness; controlled study; cost effectiveness analysis; drug cost; drug dose escalation; drug dose increase; drug dose titration; European Medicines Agency; foam; follow up; Greece; human; Italy; major clinical study; Netherlands; observational study; Portugal; Psoriasis Area and Severity Index 75; psoriasis vulgaris; Spain; systemic therapy; topical treatment; treatment duration; treatment response; United Kingdom; drug combination; psoriasis; treatment outcome, Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Humans; Psoriasis; Treatment Outcome
